Semin Arthritis Rheu: Efficacy and safety of Kanano supra-resistant treatment of Schnitzler syndrome
-
Last Update: 2020-07-13
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Schnitzler syndrome is a rare auto-inflammatory disease characterized by chronic urticaria and monoclonal propylene globulin disease, accompanied by intermittent fever, bone pain, joint pain, or arthritisKananosazumaica is a completely human-derived monoclonal anti-leconotano-1 beta (IL-1 beta) antibody that has been shown to be effective in treating auto-inflammatory diseases caused by IL-1researchers systematically retrieved the PubMed and Embase databases for all types of studies published prior to March 16, 2020 on the treatment of Schnitzler syndrome in Kananosince 2011, seven articles have reported on 34 cases of Schnitzler syndrome in Kananosau.supinaThe cumulative follow-up time was 253 months, and the follow-up time for five studies was more than 12 months58.6% of patients reported a complete response during treatment; Twenty-seven adverse events were reported in 23 patientsinfection(n-79) is the most common adverse event1 patient died of sepsis due to atypical mycobacteria infectionbased on the results of current systematic evaluation, Kananossaincanita can be effective in treating Schnitzler syndrome in the long term and is safe
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
